OncoTherapy Science (FRA:30O) Institutional Ownership: 0.30% (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
55 GF Score
Price €0.08
GF Value €0.07
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Institutional Ownership?

OncoTherapy Science FRA:30O +7.01% 55 Institutional Ownership is 0.30% as of Aug. 13, 2026. GuruFocus rates FRA:30O with a GF Score™ of 55/100 and a GF Value™ of €0.07. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OncoTherapy Science's institutional ownership is 0.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OncoTherapy Science's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OncoTherapy Science's Float Percentage Of Total Shares Outstanding is 0.00%.

OncoTherapy Science Institutional Ownership Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Institutional Ownership Chart

OncoTherapy Science Historical Data

The historical data trend for OncoTherapy Science can be seen below:

2024-11-30 2024-12-31 2025-01-31 2025-03-31 2025-04-30 2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30
Institutional Ownership 0.52 0.42 0.39 0.34 0.34 0.32 0.30 0.31 0.30 0.30
FRA:30O
55GF Score
OncoTherapy Science Inc FRA:30O
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.30% mean?
OncoTherapy Science (FRA:30O) has a Institutional Ownership of 0.30% as of Aug. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Institutional Ownership too high?
OncoTherapy Science's current Institutional Ownership is 0.30%. Overall, OncoTherapy Science has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Institutional Ownership compare to VRTX and REGN?
OncoTherapy Science's Institutional Ownership of 0.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Institutional Ownership is 0.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
OncoTherapy Science (FRA:30O) has a current Institutional Ownership of 0.30%. The stock's GF Value™ is €0.07, compared to a current price of €0.08 — trading 20% above its estimated fair value. The current Institutional Ownership is 0.30%. OncoTherapy Science's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Institutional Ownership is 0.30% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of €0.08 is trading 20% above its estimated GF Value™ of €0.07.

Key valuation signals for FRA:30O:

  • Institutional Ownership: 0.30%
  • GF Value™: €0.07 vs. price of €0.08 (20% above fair value)
  • GF Score™: 55/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
55GF Score

Get the complete analysis for FRA:30O

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.07
GF Value